JP4724348B2 - アルコール禁断症状を治療するためのｃｄｐ−コリンの使用 - Google Patents

アルコール禁断症状を治療するためのｃｄｐ−コリンの使用 Download PDF

Info

Publication number
JP4724348B2
JP4724348B2 JP2001570249A JP2001570249A JP4724348B2 JP 4724348 B2 JP4724348 B2 JP 4724348B2 JP 2001570249 A JP2001570249 A JP 2001570249A JP 2001570249 A JP2001570249 A JP 2001570249A JP 4724348 B2 JP4724348 B2 JP 4724348B2
Authority
JP
Japan
Prior art keywords
acid
choline
cdp
withdrawal symptoms
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2001570249A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003528133A5 (enExample
JP2003528133A (ja
Inventor
フォゲット、ラファエル
ラメントル、ホルゲ
ロザノ、ラファエル
アグト、フリアン
トレス、イエスズ
ラガ、マヌエル、エム
カステロ、ホセプ、エム
オルティス、ホセ、ア
Original Assignee
フエルレル インターナショナル，ソシエダッド アノニマ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by フエルレル インターナショナル，ソシエダッド アノニマ filed Critical フエルレル インターナショナル，ソシエダッド アノニマ
Publication of JP2003528133A publication Critical patent/JP2003528133A/ja
Publication of JP2003528133A5 publication Critical patent/JP2003528133A5/ja
Application granted granted Critical
Publication of JP4724348B2 publication Critical patent/JP4724348B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Addiction (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2001570249A 2000-03-29 2001-03-28 アルコール禁断症状を治療するためのｃｄｐ−コリンの使用 Expired - Fee Related JP4724348B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
ESP200000765 2000-03-29
ES200000765A ES2170649B1 (es) 2000-03-29 2000-03-29 Uso de la cdp-colina en el tratamiento de la abstinencia alcoholica.
ES200000765 2000-03-29
PCT/EP2001/003536 WO2001072288A2 (en) 2000-03-29 2001-03-28 Use of cdp-choline for the treatment of alcohol withdrawal syndrome

Publications (3)

Publication Number Publication Date
JP2003528133A JP2003528133A (ja) 2003-09-24
JP2003528133A5 JP2003528133A5 (enExample) 2007-08-09
JP4724348B2 true JP4724348B2 (ja) 2011-07-13

Family

ID=8492914

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001570249A Expired - Fee Related JP4724348B2 (ja) 2000-03-29 2001-03-28 アルコール禁断症状を治療するためのｃｄｐ−コリンの使用

Country Status (21)

Country Link
US (1) US6894032B2 (enExample)
EP (1) EP1267892B1 (enExample)
JP (1) JP4724348B2 (enExample)
KR (1) KR100794891B1 (enExample)
AT (1) ATE281172T1 (enExample)
AU (2) AU2001262141B2 (enExample)
BR (1) BR0109477A (enExample)
CA (1) CA2402707C (enExample)
CZ (1) CZ298933B6 (enExample)
DE (1) DE60106890T2 (enExample)
DK (1) DK1267892T3 (enExample)
ES (1) ES2170649B1 (enExample)
IL (2) IL151163A0 (enExample)
MX (1) MXPA02009442A (enExample)
NO (1) NO329766B1 (enExample)
NZ (1) NZ520825A (enExample)
PL (1) PL199291B1 (enExample)
PT (1) PT1267892E (enExample)
RU (1) RU2251422C2 (enExample)
WO (1) WO2001072288A2 (enExample)
ZA (1) ZA200206349B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8030294B2 (en) 2000-03-16 2011-10-04 The Mclean Hospital Corporation Compounds for the treatment of psychiatric or substance abuse disorders
EP1541154A1 (en) * 2002-07-11 2005-06-15 Yamasa Corporation Medicinal composition for drug-induced neuropathy
CN100430066C (zh) 2002-11-08 2008-11-05 麦克莱恩医院 用于烟草依赖性和戒断治疗的化合物
AU2003299715A1 (en) * 2002-12-20 2004-07-22 The Mclean Hospital Corporation Compounds for the normalization of the sleep/wake cycle
US20050129710A1 (en) * 2003-10-08 2005-06-16 Renshaw Perry F. Methods of treating psychiatric substance abuse, and other disorders using combinations containing omega-3 fatty acids
EP1765075A4 (en) 2004-06-10 2010-11-10 Mclean Hospital Corp PYRIMIDINES, AS FORM. uridine; IN THE TREATMENT OF PATIENTS WITH MANIC-DEPRESSIVE PSYCHOSIS
WO2006020703A1 (en) 2004-08-11 2006-02-23 The Mclean Hospital Corporation Compounds for the treatment of marihuana dependence, withdrawal, and usage

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5308627A (en) * 1990-08-07 1994-05-03 Umbdenstock Jr Anthony J Nutritional supplement for optimizing cellular health
RU2072239C1 (ru) * 1991-01-11 1997-01-27 Институт биохимии СО РАМН Способ коррекции метаболической зависимости от алкоголя и средство л.е.панина для его осуществления
DE4342173A1 (de) * 1993-12-10 1995-06-14 Lohmann Therapie Syst Lts Pharmazeutische Formulierung zur Prophylaxe bzw. Vorbehandlung einer Vergiftung durch phosphororganische Cholinesterasehemmer
CA2193967C (en) * 1994-07-01 2007-09-11 Reid W. Von Borstel Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis
KR100217488B1 (ko) * 1997-06-03 1999-09-01 맹섭 골프채의 헤드커버
RU2127589C1 (ru) * 1997-06-03 1999-03-20 Порембский Ярослав Олегович Способ лечения стрессорных поражений нервной системы
US5958896A (en) * 1997-08-08 1999-09-28 The Mclean Hospital Cytidine-containing and cytosine-containing compounds as treatments for stimulant exposure
US8030294B2 (en) 2000-03-16 2011-10-04 The Mclean Hospital Corporation Compounds for the treatment of psychiatric or substance abuse disorders

Also Published As

Publication number Publication date
DK1267892T3 (da) 2005-03-07
EP1267892B1 (en) 2004-11-03
NO20024574L (no) 2002-11-22
ES2170649A1 (es) 2002-08-01
ATE281172T1 (de) 2004-11-15
WO2001072288A3 (en) 2002-05-10
EP1267892A2 (en) 2003-01-02
MXPA02009442A (es) 2003-02-12
PT1267892E (pt) 2005-03-31
US6894032B2 (en) 2005-05-17
CZ298933B6 (cs) 2008-03-12
NZ520825A (en) 2004-04-30
BR0109477A (pt) 2003-06-03
KR20030005248A (ko) 2003-01-17
PL199291B1 (pl) 2008-09-30
AU6214101A (en) 2001-10-08
KR100794891B1 (ko) 2008-01-14
DE60106890T2 (de) 2005-11-03
NO329766B1 (no) 2010-12-13
PL363177A1 (en) 2004-11-15
ZA200206349B (en) 2003-08-08
WO2001072288A2 (en) 2001-10-04
US20030162749A1 (en) 2003-08-28
CA2402707A1 (en) 2001-10-04
ES2170649B1 (es) 2003-06-16
NO20024574D0 (no) 2002-09-24
IL151163A0 (en) 2003-04-10
RU2002129579A (ru) 2004-03-27
RU2251422C2 (ru) 2005-05-10
DE60106890D1 (de) 2004-12-09
AU2001262141B2 (en) 2005-03-10
CZ20023245A3 (cs) 2003-03-12
IL151163A (en) 2011-01-31
JP2003528133A (ja) 2003-09-24
CA2402707C (en) 2007-11-13

Similar Documents

Publication Publication Date Title
US5854238A (en) Use of a thienotriazolodiazephine to increase apolipoprotein A-I levels
JP4724348B2 (ja) アルコール禁断症状を治療するためのｃｄｐ−コリンの使用
WO2022104022A1 (en) Rapidly infusing compositions with methotrexate and treatment methods
CN116940362A (zh) 在慢性ssri方案后使用苯二氮䓬增加对裸盖菇素的敏感性
JP3942207B2 (ja) うつ性症状改善剤
CN100413496C (zh) 丁二酸衍生物酯类化合物在制备治疗痴呆症的药物中的用途
AU2007325972A1 (en) S-nitrosothiol compounds and related derivatives
CN111184731A (zh) 人参皂苷Rg5在制备用于改善睡眠的药物组合物中的用途
US20050171051A1 (en) Pharmaceutical composition for diabetic neuropathy
EP2830641B1 (en) New valerian extracts and uses thereof
JP2004026813A (ja) 医薬組成物
WO1992007564A2 (en) Method of treating demyelinating disease
WO2002085341A2 (en) Composition, containing carnitine and huperzin for the preventionor treatment of learning disorders in children suffering from attention deficit/hyperactive disorder
EP1306378A1 (en) Dementia remedies containing 2-aryl-8-oxodihydropurine derivatives as the active ingredient
WO2023036105A1 (zh) 治疗神经退行性疾病的方法
US20090054461A1 (en) Pharmaceutical composition comprising a 1-(3-chlorophenyl)-3-alkylpiperazine for treating apetite disorder
AU2001282510A1 (en) Composition, containing carnitine and huperzin for the prevention or treatment of learning disorders in children suffering from attention deficit/hyperactive disorder

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070619

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070619

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110215

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110401

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110411

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140415

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 4724348

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees